Dublin, Dec. 14, 2018 (GLOBE NEWSWIRE) -- The "Global Von Willebrand Disease Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The von Willebrand disease treatment market will register a CAGR of almost 7% by 2023.

The increasing awareness about VWD is likely to boost growth in the market. VWD will be present in the affected individual since the time of birth; however, the symptoms do not appear from childhood. Patients' perceptions of symptoms such as frequent nosebleeds, staining and extreme bleeding during and after invasive events such as dental extractions and surgical procedures are general changing gradually.

Market Overview

Rising number of assistance programs for patients

The rising number of assistance programs for patients who need treatment of von Willebrand disease is pushing growth in the von Willebrand disease treatment market.

Cost intensive treatment

High cost of treatment is one of the major challenges for patients with VWD. As VWD is one of the very rare blood diseases, the patient pool available for carrying out clinical trials is negligible, which increases the research cost.

Competitive Landscape

The market appears to be highly concentrated and with the presence of few companies including Baxter and CSL, the competitive environment is quite intense. Factors such as the increasing awareness about VWD and the rising number of assistance programs for patients, will provide considerable growth opportunities to von Willebrand disease treatment manufactures. Baxter, CSL, Octapharma, Shire, and Grifols are some of the major companies covered in this report.

With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

• Preface
• Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

• Market segmentation by product
• Comparison by product
• Desmopressin - Market size and forecast 2018-2023
• Replacement therapy - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Baxter
• CSL
• Grifols
• Octapharma
• Shire

PART 14: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/t9rv5x/global_von?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematology , Hematological Drugs